In vitro activities of anidulafungin against more than 2,500 clinical isolates of Candida spp., including 315 isolates resistant to fluconazole

被引:127
作者
Pfaller, MA
Boyken, L
Hollis, RJ
Messer, SA
Tendolkar, S
Diekema, DJ
机构
[1] Univ Iowa, Div Med Microbiol, Dept Pathol, Coll Med, Iowa City, IA 52242 USA
[2] Univ Iowa, Dept Epidemiol, Coll Med, Iowa City, IA 52242 USA
[3] Univ Iowa, Dept Med, Coll Med, Iowa City, IA 52242 USA
[4] Coll Publ Hlth, Iowa City, IA 52242 USA
关键词
D O I
10.1128/JCM.43.11.5425-5427.2005
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Anidulafungin is an echinocandin antifungal agent with potent activity against Candida spp. We assessed the in vitro activity of anidulafungin against 2,235 clinical isolates of Candida spp. using the CLSI broth microdilution method. Anidulafungin was very active against Candida spp. (the MIC at which 90% of strains are inhibited [MIC90] was 2 mu g/ml when MIC endpoint criteria of partial inhibition [MIC-2] were used). Candida albicans, C. glabrata, C. tropicalis, C. krusei, and C. kefyr were the most susceptible species of Candida (MIC90, 0.06 to 0.12 mu g/ml), and C parapsilosis, C lusitaniae, and C guilliermondii were the least susceptible (MIC90, 0.5 to 2 mu g/ml). In addition, 315 fluconazole-resistant isolates were tested, and 99% were inhibited by <= 1 mu g/ml of anidulafungin. These results provide further evidence for the spectrum and potency of anidulafungin activity against a large and geographically diverse collection of clinically important isolates of Candida spp.
引用
收藏
页码:5425 / 5427
页数:3
相关论文
共 18 条
  • [1] Antifungal activity of the echinocandin anidulafungin (VER002, LY-303366) against yeast pathogens:: a comparative study with M27-A microdilution method
    Arévalo, MP
    Carrillo-Muñoz, AJ
    Salgado, J
    Cardenes, D
    Brió, S
    Quindós, G
    Espinel-Ingroff, A
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2003, 51 (01) : 163 - 166
  • [2] Quality control limits for broth microdilution susceptibility tests of ten antifungal agents
    Barry, AL
    Pfaller, MA
    Brown, SD
    Espinel-Ingroff, A
    Ghannoum, MA
    Knapp, C
    Rennie, RP
    Rex, JH
    Rinaldi, MG
    [J]. JOURNAL OF CLINICAL MICROBIOLOGY, 2000, 38 (09) : 3457 - 3459
  • [3] Influences of methodological variables on susceptibility testing of caspofungin against Candida species and Aspergillus fumigatus
    Bartizal, C
    Odds, FC
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2003, 47 (07) : 2100 - 2107
  • [4] Susceptibility of fluconazole-resistant clinical isolates of Candida spp. to echinocandin LY303366, itraconazole and amphotericin B
    Cuenca-Estrella, M
    Mellado, E
    Díaz-Guerra, TM
    Monzón, A
    Rodríguez-Tudela, JL
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2000, 46 (03) : 475 - 477
  • [5] Postantifungal effects of echinocandin, azole, and polyene antifungal agents against Candida albicans and Cryptococcus neoformans
    Ernst, EJ
    Klepser, ME
    Pfaller, MA
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (04) : 1108 - 1111
  • [6] Pharmacokinetic and pharmacodynamic modeling of anidulafungin (LY303366): Reappraisal of its efficacy in neutropenic animal models of opportunistic mycoses using optimal plasma sampling
    Groll, AH
    Mickiene, D
    Petraitiene, R
    Petraitis, V
    Lyman, CA
    Bacher, JS
    Piscitelli, SC
    Walsh, TJ
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (10) : 2845 - 2855
  • [7] Hazen K C., 2003, Manual of clinical microbiology, V8, P1693
  • [8] Phase 2, randomized, dose-ranging study evaluating the safety and efficacy of anidulafungin in invasive candidiasis and candidemia
    Krause, DS
    Reinhardt, J
    Vazquez, JA
    Reboli, A
    Goldstein, BP
    Wible, M
    Henkel, T
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2004, 48 (06) : 2021 - 2024
  • [9] National Committee for Clinical Laboratory Standards, 2002, M27A2
  • [10] Interlaboratory comparison of results of susceptibility testing with caspofungin against Candida and Aspergillus species
    Odds, FC
    Motyl, M
    Andrade, R
    Bille, J
    Cantón, E
    Cuenca-Estrella, M
    Davidson, A
    Durussel, C
    Ellis, D
    Foraker, E
    Fothergill, AW
    Ghannoum, MA
    Giacobbe, RA
    Gobernado, M
    Handke, R
    Laverdière, M
    Lee-Yang, W
    Merz, WG
    Ostrosky-Zeichner, L
    Pemán, J
    Perea, S
    Perfect, JR
    Pfaller, MA
    Proia, L
    Rex, JH
    Rinaldi, MG
    Rodriguez-Tudela, JL
    Schell, WA
    Shields, C
    Sutton, DA
    Verweij, PE
    Warnock, DW
    [J]. JOURNAL OF CLINICAL MICROBIOLOGY, 2004, 42 (08) : 3475 - 3482